{"id":30764,"date":"2025-04-25T12:47:13","date_gmt":"2025-04-25T10:47:13","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/04\/25\/an-antigen-less-pro-vaccine-for-treating-autoimmunity\/"},"modified":"2025-04-25T12:47:13","modified_gmt":"2025-04-25T10:47:13","slug":"an-antigen-less-pro-vaccine-for-treating-autoimmunity","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/04\/25\/an-antigen-less-pro-vaccine-for-treating-autoimmunity\/","title":{"rendered":"An antigen-less pro-vaccine for treating autoimmunity"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2025 Apr 24:vkaf068. doi: 10.1093\/jimmun\/vkaf068. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>We have designed the first antigen-less pro-vaccine, named 8206, for treating autoimmune diseases. Composed of dexamethasone, rapamycin, and R848 at a mass ratio of 8:20:6, 8206 is a complete tolerogenic adjuvant that acts systemically to form an active vaccine in situ with endogenous pathogenic autoantigens. This active vaccine suppresses autoimmunity by expanding antigen-specific Treg cells in affected tissues. In a mouse model of atherosclerosis, 8206 successfully targeted all three analyzed pathogenic autoantigens (ApoB, HSP60, and HMGB1) and inhibited disease progression. These findings suggest that 8206 can potentially serve as a universal treatment vaccine for autoimmune diseases by eliminating the need for exogenous immunogens, with implications for broad applications in immunotherapy.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40275513\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20250425064711&amp;v=2.18.0.post9+e462414\">40275513<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkaf068\">10.1093\/jimmun\/vkaf068<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2025 Apr 24:vkaf068. doi: 10.1093\/jimmun\/vkaf068. Online ahead of print. ABSTRACT We have designed the first antigen-less pro-vaccine, named 8206, for treating autoimmune diseases. Composed of dexamethasone, rapamycin, and R848 at a mass ratio of 8:20:6, 8206 is a complete tolerogenic adjuvant that acts systemically to form an active vaccine in situ with endogenous &#8230; <a title=\"An antigen-less pro-vaccine for treating autoimmunity\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/04\/25\/an-antigen-less-pro-vaccine-for-treating-autoimmunity\/\" aria-label=\"Read more about An antigen-less pro-vaccine for treating autoimmunity\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-30764","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/30764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=30764"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/30764\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=30764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=30764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=30764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}